Intérêts de la centralisation de la chirurgie du cancer de l’ovaire en France

Meurette, J; Daraı̈, Émile; Tajahmady, Ayden; Fouard, Annie; Ducastel, Anne; Collin-Bund, Virginie; Jochum, Floriane; Lecointre, Lise; Querleu, Denis; Akladios, Chérif

doi:10.1016/j.bulcan.2022.12.016

Cited by 4 publications

(1 citation statement)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our study has shown that there is a significant increase in post-operative complications, mostly grade III complications, that has already been described in other centers implementing radical surgery. 16 …”

Section: Discussionmentioning

confidence: 99%

Centralizing surgery for ovarian cancer in a ‘non-centralizing’ country (Belgium): the UNGO (UCLouvain Network of Gynaecological Oncology) experience

Luyckx,

Jouret,

Sawadogo

et al. 2023

Int J Gynecol Cancer

View full text Add to dashboard Cite

ObjectiveIn Belgium there is no centralization of surgery for ovarian cancer, with more than 100 centers treating around 800 cases per year. In 2017 a network with several collaborating hospitals was established to centralize surgery for ovarian cancer (UCLouvain Network of Gynecological Oncology; UNGO) following publication of the European Society of Gynecological Oncology (ESGO) recommendations and quality criteria for surgery of advanced ovarian cancer. We obtained ESGO accreditation in 2019.MethodsWe retrospectively collected data associated with patients undergoing surgery in our institution from 2007 to 2016, before the creation of the network (cohort 1) and, following the establishment of UNGO (2017–2021), patients undergoing surgery were prospectively registered in a REDCap database (cohort 2). The outcomes of the two cohorts were compared.ResultsA total of 314 patients underwent surgery in our institution from 2007 and 2021: 7.5 patients/year in cohort 1 (retrospective, 2007–2016) and 40.8 patients/year in cohort 2 (after network creation, 2017–2021). Median disease-free survival was increased from 16.5 months (range 13.2–20.4) in cohort 1 to 27.1 months (range 21.5–33.2) in cohort 2 (p=0.0004). In cohort 2, the rate of patients with residual disease at the end of the surgery was significantly less (18.7% vs 8.8%, p=0.023), although more patients in cohort 1 received neoadjuvant chemotherapy (89% vs 54%, p<0.001). However, there was a higher rate of complications in the patients in cohort 2 (18.8% vs 30%, p=0.041).ConclusionOur study shows that, with the help of ESGO and its recommendations, we have been able to create an efficient advanced ovarian cancer centralized network and this may provide an improvement in the quality of care.

show abstract

Section: Discussionmentioning

confidence: 99%